]>
IRCT201012042085N6 IRCT 2011-01-20 Shahrekord University Of Medical Sciences Survey of Alhagi pseudalhagi effect on blood bilirubin in neonates with hyperbilirubinemia in Shahrekord Hajar hospital Survey of Alhagi pseudalhagi effect on blood bilirubin in neonates with hyperbilirubinemia in Shahrekord Hajar hospital 2010-03-21 anticipated 124 Complete https://irct.ir/trial/1704 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. N/A hyperbilirubinemia. Intervention 1: The mother and neonate received Alhagi pseudalhagi 25% cocentration solution, 30 cc and 1cc/kg, respectively, every 8 hours as well as phototherapy until the serum level of bilirubin decreased to the normal level. Intervention 2: The mother only received Alhagi pseudalhagi 25% cocentration solution, 30 cc every 8 hours as well as phototherapy for the neonates until the serum level of bilirubin decreased to the normal level. Intervention 3: In the control group, neither mother nor neonate received the solution. The neonates only received phototherapy until the serum level of bilirubin decreased to the normal level. Intervention 4: The neonate only received Alhagi pseudalhagi 25% cocentration solution, 1 cc/kg, every 8 hours as well as phototherapy until the serum level of bilirubin decreased to the normal level.
public
scientific Neda Parvin
Shahrekord University Of Medical Sciences
Shahrekord University Of Medical Sciences Iran (Islamic Republic of) +98 38 1334 6692 np285@yahoo.com Shahrekord University Of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: Signing informed consent by parents, total serum bilirubin between 14 and 20 mg/dL, presence of Non hemolytic hyperbilirubinemia, presence of indirect hyperbilirubinemia, hyperbilirubinemia which starts between the third and tenth days after birth, term infant, (Gestational age 42-37 weeks), birth weight 4-5/2 Kg, exclusive breast feeding, Ability of mother to attend the neonate’s bedside, no congenital anomaly, no sepsis, history of asphyxia, or traumatic delivery, no cephalohematoma, no history of neonatal jaundice, no previous treatment for jaundice, any other treatments or hospitalization, no other treatment with antibiotic or other drugs Exclusion criteria: discharge for any reason before bilirubin less than 12mg/dl, need to other drugs during treatment 1 year 1 year Both P59 Neonatal jaundice from other and unspecified causes Treatment - Drugs Treatment - Drugs Treatment - Other Treatment - Drugs The mother and neonate received Alhagi pseudalhagi 25% cocentration solution, 30 cc and 1cc/kg, respectively, every 8 hours as well as phototherapy until the serum level of bilirubin decreased to the normal level. The mother only received Alhagi pseudalhagi 25% cocentration solution, 30 cc every 8 hours as well as phototherapy for the neonates until the serum level of bilirubin decreased to the normal level. In the control group, neither mother nor neonate received the solution. The neonates only received phototherapy until the serum level of bilirubin decreased to the normal level. The neonate only received Alhagi pseudalhagi 25% cocentration solution, 1 cc/kg, every 8 hours as well as phototherapy until the serum level of bilirubin decreased to the normal level. Serum level of bilirubin. Timepoint: Baseline and then daily during the study. Method of measurement: blood sample. Hospital stay. Timepoint: During hospital stay. Method of measurement: The number of days that neonate is hospitalized. Shahrekord University Of Medical Sciences Approved 2009-02-20 Shahrekord University of Medical Sciences Shahrekord University of Medical Sciences Shahrekord Iran (Islamic Republic of)